Recently, in a study investigating the clinical significance of p53 alterations in prostate cancer, an immunohistochemistry protocol that was deliberately designed to be “oversensitive” resulted in a much higher rate of positive immunohistochemical findings (2.5% positivity with the standard protocol compared with greater than 90% positivity with the “oversensitive” protocol) [42]. The gene discussed is TP53; the disease is prostate carcinoma.